RESUMEN
Escherichia phages Carena and JoYop were isolated from water samples in Abidjan (Cote d'Ivoire). Their genomes comprise 39,283 and 169,193 bp, encoding 44 and 246 predicted genes, respectively. Carena shares 93.4% nucleotide identity with Escherichia podophage CarlSpitteler (Berlinvirus), and JoYop shows 95.6% identity with Escherichia myophage ADUt (Tequatrovirus).
RESUMEN
INTRODUCTION: Yaws, caused by the bacterium Treponema pallidum subsp. pertenue, is a neglected tropical disease targeted for eradication by 2030. Improved diagnostics will be essential to meet this goal. Diagnosis of yaws has relied heavily on clinical and serological tools. However, the presence of coendemic cutaneous skin ulcer diseases, such as lesions caused by Haemophilus ducreyi (HD), means these techniques do not provide a reliable diagnosis. Thus, new diagnostic tools are needed. Molecular tools such as PCR are ideal, but often expensive as they require trained technicians and laboratory facilities, which are often not available to national yaws programmes. METHODS AND ANALYSIS: The LAMP4yaws project is a cross-sectional, observational, diagnostic accuracy study of a combined Treponema pallidum (TP) and HD loop mediated isothermal amplification (TPHD-LAMP) test performed under real world conditions in three endemic countries in West Africa. Individuals with serologically confirmed yaws will be recruited in Cameroon, Côte d'Ivoire and Ghana. Each participant will provide paired swabs, one of which will be sent to the respective national reference laboratory for yaws quantitative PCR and the other will be tested for both TP and HD using the TPHD-LAMP test at local district laboratories. Sensitivity and specificity of the TPHD-LAMP test will be calculated against the reference standard qPCR. We will also assess the acceptability, feasibility and cost-effectiveness of the test. We anticipate that results from this study will support the adoption of the TPHD-LAMP test for use in global yaws eradication efforts. ETHICS AND DISSEMINATION: We have received ethical approval from all relevant institutional and national ethical committees. All participants, or their parents or guardians, must provide written informed consent prior to study enrolment. Study results will be published in an open access journal and disseminated with partners and the World Health Organization. TRIAL REGISTRATION NUMBER: NCT04753788.
Asunto(s)
Haemophilus ducreyi , Úlcera Cutánea , Buba , Estudios Transversales , Ghana , Haemophilus ducreyi/genética , Humanos , Técnicas de Diagnóstico Molecular , Técnicas de Amplificación de Ácido Nucleico , Estudios Observacionales como Asunto , Reacción en Cadena en Tiempo Real de la Polimerasa , Treponema , Treponema pallidum/genética , Buba/diagnóstico , Buba/epidemiología , Buba/microbiologíaRESUMEN
The lytic Escherichia coli siphophage BRET was isolated from a chicken obtained at a local market in Abidjan, Côte d'Ivoire. Its linear genome sequence consists of 59,550 bp (43.4% GC content) and contains 88 predicted genes, including 4 involved in archaeosine biosynthesis. Phage BRET is related (95% nucleotide identity) to Enterobacteria phage JenK1.
RESUMEN
The lytic Escherichia coli phage Ebrios was isolated from a water sample collected in Ebrie Lagoon on the Adiopodoumé River in Abidjan (Republic of Côte d'Ivoire, West Africa). The linear genome of this Podoviridae family member contains 39,752 bp, has a G+C content of 52.9%, is composed of 53 open reading frames, and is related to the Stenotrophomonas maltophilia phage IME15.